 | |
| Clinical data | |
|---|---|
| Drug class | Opioid |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H27FN2O |
| Molar mass | 354.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NFEPP (N-(3-fluoro-1-phenethylpiperidin-4-yl)-N-phenylpropionamide) is ananalgesicopioid chemical, similar in structure tofentanyl, designed in 2016 by Spahnet al. fromFree University of Berlin[2] to avoid thestandard negative side effects of opiates, includingopioid overdose, by only targetinginflamed tissue.[3][4]
Inflamed tissue has a lowerpH value (~5–7) than non-inflamed tissue (7.4).[5] Throughcomputer simulation, scientists found a way to make the fentanyl analog only affect inflamed tissue via the addition offluorine to the chemical structure. In experiment, it was shown that NFEPP produced injury-restricted analgesia in rats with different types of inflammatory pain without exhibiting typical opiate effects, includingrespiratory depression,sedation,constipation, and chemical seeking behavior.[6][7][8]
As a result, NFEPP has the potential to reduceopioid addiction and dependency, as there is no effect on users who are not actually suffering frompain, as the chemical does not interact with non-inflamed brain tissue until much higher doses are reached.[9]
